By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AB Science 

3, Avenue George V

Paris    75008  France
Phone: 33-(0)1-47200014 Fax: 33-(0)1-47202411



Company News
French Regulators Order AB Science (AB.PA) To Temporarily Suspend Work On Phase III ALS Trial 5/12/2017 5:36:24 AM
AB Science (AB.PA) Announces The Filing Of Masitinib In The Treatment Of Amyotrophic Lateral Sclerosis (ALS) To The EMA 9/30/2016 7:26:55 AM
AB Science (AB.PA) Release: Action Plan Following Warning Letter Has Been Validated By FDA 7/14/2016 10:47:02 AM
AB Science (AB.PA) Will Hold An Investor & Analyst Conference On Masitinib In Amyotrophic Lateral Sclerosis (ALS) In New York, USA, On June 13, 2016 6/9/2016 7:40:02 AM
AB Science (AB.PA) Announces Initiation Of An Adaptive Design Phase II/III Study With Masitinib In Patients With Refractory Metastatic Ovarian Cancer 7/15/2015 10:37:44 AM
AB Science (AB.PA) Studies Banned in France Due to Side Effects 7/9/2015 6:37:56 AM
AB Science (AB.PA): Masitinib Receives Orphan Drug Designation For Amyotrophic Lateral Sclerosis From FDA 3/23/2015 9:13:47 AM
AB Science (AB.PA) : Positive Phase II Clinical Study Data Of Masitinib In Triple Negative Breast Cancer 3/13/2015 7:14:47 AM
AB Science (AB.PA) : Successful Completion Of Futility Test For Masitinib In Alzheimer's Disease 2/10/2015 7:46:11 AM
AB Science (AB.PA): Positive Phase 2 Clinical Study Data Of Masitinib In Second-Line Metastatic Stomach Cancer 2/3/2015 7:14:16 AM